Article
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
13 Dec 2017
Abstract excerpt
BACKGROUND: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus. METHODS: We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
